Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics reported progress across its high-priority programs, including completing dosing for the BEACON Phase 1/2 Trial of BEAM-101 in sickle cell disease and initiating a trial for BEAM-302 in alpha-1 antitrypsin deficiency. The company ended the first quarter of 2024 with $1.1 billion in cash and expects to support its operating plans into 2027.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.